JP2023529026A5 - - Google Patents

Info

Publication number
JP2023529026A5
JP2023529026A5 JP2023517825A JP2023517825A JP2023529026A5 JP 2023529026 A5 JP2023529026 A5 JP 2023529026A5 JP 2023517825 A JP2023517825 A JP 2023517825A JP 2023517825 A JP2023517825 A JP 2023517825A JP 2023529026 A5 JP2023529026 A5 JP 2023529026A5
Authority
JP
Japan
Prior art keywords
cancer
subject
activity
immunotherapy
copy number
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023517825A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023529026A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/035205 external-priority patent/WO2021247540A1/en
Publication of JP2023529026A publication Critical patent/JP2023529026A/ja
Publication of JP2023529026A5 publication Critical patent/JP2023529026A5/ja
Pending legal-status Critical Current

Links

JP2023517825A 2020-06-01 2021-06-01 Ｍｈｃ－ｉ発現を調節するための方法及びその免疫療法の使用 Pending JP2023529026A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063032956P 2020-06-01 2020-06-01
US63/032,956 2020-06-01
US202063039211P 2020-06-15 2020-06-15
US63/039,211 2020-06-15
PCT/US2021/035205 WO2021247540A1 (en) 2020-06-01 2021-06-01 Methods for modulating mhc-i expression and immunotherapy uses thereof

Publications (2)

Publication Number Publication Date
JP2023529026A JP2023529026A (ja) 2023-07-06
JP2023529026A5 true JP2023529026A5 (enExample) 2024-06-11

Family

ID=78829900

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023517825A Pending JP2023529026A (ja) 2020-06-01 2021-06-01 Ｍｈｃ－ｉ発現を調節するための方法及びその免疫療法の使用

Country Status (4)

Country Link
US (1) US20230203485A1 (enExample)
EP (1) EP4161658A4 (enExample)
JP (1) JP2023529026A (enExample)
WO (1) WO2021247540A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7652713B2 (ja) * 2019-05-27 2025-03-27 ビジョン ファーマ ピーティーワイ リミテッド 新規の網膜色素変性処置
CN113249382B (zh) * 2021-04-12 2023-05-12 右江民族医学院 下调TRIM56基因表达的siRNA及其应用
CN114694748B (zh) * 2022-02-22 2022-10-28 中国人民解放军军事科学院军事医学研究院 一种基于预后信息与强化学习的蛋白质组学分子分型方法
CN114805553B (zh) * 2022-04-13 2024-06-18 武汉大学 蛋白ZYG11B在制备用于促进cGAS的酶活性的药物中的应用
CN116179543B (zh) * 2022-07-06 2024-08-13 四川农业大学 基于CRISPR特异性靶向猪Cavin-1基因的sgRNA及应用
AU2023315762A1 (en) * 2022-07-25 2025-01-30 Immunitybio, Inc. Treatment of mhc-i negative tumors with nk and t cells
WO2024137817A1 (en) * 2022-12-23 2024-06-27 Ventana Medical Systems, Inc. Materials and methods for evaluation of antigen presentation machinery components and uses thereof
CN117069838B (zh) * 2023-10-13 2023-12-08 广东赛尔生物科技有限公司 Aoh1160和抗体联合治疗癌症的用途
CN117538544A (zh) * 2023-11-22 2024-02-09 湛江中心人民医院 检测基因Ccdc181表达量的试剂在制备精子异常诊断产品中的应用
WO2025171164A1 (en) * 2024-02-07 2025-08-14 Board Of Regents, The University Of Texas System Gene signatures predictive of cancer cell response to immunomodulatory therapy
CN118186089B (zh) * 2024-04-02 2024-11-12 中山大学附属第一医院 Nit2在胃癌化疗增敏中的应用
WO2025212419A1 (en) * 2024-04-05 2025-10-09 Genecentric Therapeutics, Inc. Method for assessing microsatellite instability and homologous recombination repair deficiency in cancer
CN118021995B (zh) * 2024-04-11 2024-06-11 南昌大学第一附属医院 多肽在制备用于预防和/或治疗骨肉瘤的药物中的应用
CN118759189B (zh) * 2024-07-11 2025-07-04 浙江省肿瘤医院 用于诊断宫颈癌淋巴转移的生物标记物及其应用
CN118955595A (zh) * 2024-07-29 2024-11-15 四川大学 一种治疗i型超敏反应的药物
CN118566508B (zh) * 2024-08-02 2025-04-08 德州市红拳医疗器械有限公司 一种用于检测胃癌标志物的试剂盒及其应用
CN119955928B (zh) * 2025-02-11 2025-11-07 中山大学中山眼科中心 Serpind1抑制剂在制备用于治疗湿性年龄相关性黄斑变性药物中的应用
CN120594834B (zh) * 2025-08-08 2025-10-28 山东大学 一种针对echs1 k115位点的胰腺癌治疗靶点及应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0917457D0 (en) * 2009-10-06 2009-11-18 Glaxosmithkline Biolog Sa Method
BR112015023120A2 (pt) * 2013-03-15 2017-11-21 Genentech Inc método para identificar um indivíduo com uma doença ou disfunção, método para prever a responsividade de um indivíduo com uma doença ou disfunção, método para determinar a probabilidade de que um indivíduo com uma doença ou disfunção exibirá benefício do tratamento, método para selecionar uma terapia, usos de um antagonista de ligação do eixo pd-l1, ensaio para identificar um indivíduo com uma doença, kit de diagnóstico, método para avaliar uma resposta ao tratamento e método para monitorar a resposta de um indivíduo tratado
WO2015058780A1 (en) * 2013-10-25 2015-04-30 Biontech Ag Method and kit for determining whether a subject shows an immune response
US9717717B1 (en) * 2015-07-31 2017-08-01 Progenra, Inc. Methods of treating cancer through the inhibition of USP7 and immune system modulation
WO2018132825A2 (en) * 2017-01-16 2018-07-19 Memorial Sloan Kettering Cancer Center Treatment of sarcoma
WO2018160944A1 (en) * 2017-03-03 2018-09-07 Progenra, Inc. Azole compounds as ubiquitin-specific protease usp7 inhibitors
CA3096287A1 (en) * 2018-01-22 2019-07-25 Pascal Biosciences Inc. Cannabinoids and derivatives for promoting immunogenicity of tumor and infected cells

Similar Documents

Publication Publication Date Title
JP2023529026A5 (enExample)
US10706954B2 (en) Systems and methods for identifying responders and non-responders to immune checkpoint blockade therapy
Sato-Kaneko et al. Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancer
US20240209103A1 (en) Patient selection methods and kits for therapies targeting tl1a
KR20110036610A (ko) 신규 온코진 ｎｒｆ2
CN109963572A (zh) 用于表征实体瘤对抗pd-l1抗体单一疗法的反应性的组合物和方法
CN112739826A (zh) 抗体-药物缀合物的敏感性标志物
JP2021502329A5 (enExample)
JP2020143122A (ja) Ｉｇｆ−１ｒ抗体および癌の診断のためのその使用
US20110027297A1 (en) Methods Involving MS4A12 and Agents Targeting MS4A12 for Therapy, Diagnosis and Testing
CN117607433A (zh) Pltp作为预测肝癌免疫治疗效果的生物标志物和靶点的应用
KR102350259B1 (ko) Igf-1r 항체 및 암의 진단을 위한 그의 용도
JP7593669B2 (ja) コンパニオン診断用バイオマーカー組成物およびこれを含むコンパニオン診断用キット
JP2025506706A (ja) がん患者に対する免疫チェックポイント阻害剤の反応性予測用組成物
CN113508141A (zh) 抗体及其功能片段
CN115516111A (zh) 治疗癌症的方法
CA3065568C (en) Systems and methods for identifying responders and non-responders to immune checkpoint blockade therapy
WO2026050568A1 (en) Methods and uses for treating cancer using antibody-drug conjugates
WO2025081121A1 (en) Methods, kits and systems for determining the status of lung cancer and methods for treating lung cancer based on same
WO2025081121A9 (en) Methods, kits and systems for determining the status of lung cancer and methods for treating lung cancer based on same
CN118028466A (zh) Slc6a6基因在作为肿瘤标志物和肿瘤治疗靶点中的应用
CN120505416A (zh) Iv型胶原蛋白及其编码基因在复发鼻咽癌预后评估和治疗中的应用
HK40096569A (zh) 抗pd-1抗体在制备治疗尿路上皮癌的药物中的用途
Cabrera et al. P3. 04-13 PD-L1-Gene Expression by nCounter Correlates with PD-L1 Protein Expression in Advanced Non-Small Cell Lung Cancer (NSCLC)
RU2021119549A (ru) Способы и фармацевтические композиции для усиления cd8+ t-клеточных иммунных ответов у субъектов, страдающих от рака